海外消费服务 2026年02月08日 版 发行业 相关研究 #研究 证券分析师 黄哲 A0230513030001 huangzhe@swsresearch.com 周文远 A0230518110003 zhouwy@swsresearch.com 贾梦迪 A0230520010002 jiamd@swsresearch.com 册 分歧了后 胡梦婷 A0230524060004 humt@swsresearch.com 联系人 胡梦婷 A0230524060004 humt@swsresearch.com 申万宏源研究微信服务号 港股医药 2025 年报业绩前瞻: 商业化销售放量叠加 授权收入,部分公司有望迎来盈利拐点 -海外消费周报（20260130-20260205） 海外医药：港股医药 2025 年报业绩前瞻——商业化销售放量叠加授权收入，部分公司 ● 有望迎来盈利拐点 创新药：商业化销售放量叠加授权收入，部分公司有望迎来盈利拐点。创新药板块，我 们预计 2025 年有望实现盈利的公司包括：百济神州、信达生物、荣昌生物、复宏汉 霖、诺诚健华，以及和黄医药等，主要由于核心产品的商业化销售放量以及 BD ...

行 业 及 产 业 海外消费服务 行 业 研 究 / 行 业 点 评 相关研究 证 券 研 究 报 告 证券分析师 黄哲 A0230513030001 huangzhe@swsresearch.com 周文远 A0230518110003 zhouwy@swsresearch.com 贾梦迪 A0230520010002 jiamd@swsresearch.com 研究支持 胡梦婷 A0230524060004 humt@swsresearch.com 联系人 胡梦婷 A0230524060004 2026 年 02 月 08 日 港股医药 2025 年报业绩前瞻：商业化销售放量叠加 授权收入，部分公司有望迎来盈利拐点 看好 ——海外消费周报（20260130-20260205） 本期投资提示： ⚫ 海外医药：港股医药 2025 年报业绩前瞻——商业化销售放量叠加授权收入，部分公司 有望迎来盈利拐点 创新药：商业化销售放量叠加授权收入，部分公司有望迎来盈利拐点。创新药板块，我 们预计 2025 年有望实现盈利的公司包括：百济神州、信达生物、荣昌生物、复宏汉 霖、诺诚健华，以及和黄医药等，主要由于核心产品的商业 ...

香港《南华早报》指出，声明显示这并非丘应桦首次召见巴拿马总领事。CEDB对此前会面的具体情况 不予置评。 据报道，港府采取上述行动前，本周三（4日），香港长和发表公告，宣布其旗下的巴拿马港口公司 （PPC）已就巴拿马最高法院日前的裁决提起仲裁，斥责巴方行动导致公司遭受"严重且迫在眉睫的损 失"，将寻求"广泛的赔偿"。 国务院港澳事务办公室3日在评论中也态度强硬地批评巴拿马的裁决"荒谬至极""屈从霸权、为虎作 伥"，要求巴方"认清形势、迷途知返"，并警告说"如果一意孤行，执迷不悟，必将在政治上、经济上都 付出沉重代价"！ 巴拿马总统何塞·劳尔·穆利诺周四声称，希望香港企业运营巴拿马运河港口引发的法律纠纷"不要升 级"，但仍强调巴拿马政府坚决维护法院的所谓裁决。 面对中方批评，这名早已屈从于美国胁迫的总统竟还振振有词称，"巴拿马是有尊严的国家，绝不会容 忍世界上任何国家的威胁。"他还宣称，巴拿马"绝不再"将运河两端港口的特许经营权交由单一公司运 营。 据港媒报道，联合国国际贸易法委员会法规判例法中国国家联络员、香港地区大律师黎逸轩分析称，若 长和在仲裁中胜诉并寻求金钱赔偿，可根据《纽约公约》（《承认及执行外国仲裁 ...

Investment Rating - The report provides an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, indicating a positive outlook for these stocks [1]. Core Insights - The macro and industry environment is improving due to the resolution of policy uncertainties, the release of significant clinical data, and a resurgence in global M&A activity, leading to a notable increase in investor sentiment towards innovative drugs for 2026 [4][11]. - In oncology, the PD-1/VEGF dual antibody approach is transitioning from "mechanism validation" to "clinical and industrial resonance," with multiple global Phase III trials underway, expected to catalyze approvals and data releases within the year [5][17]. - The metabolic sector is seeing growth in the cash-pay market for GLP-1 drugs, driven by limited insurance coverage and high out-of-pocket costs, prompting companies to enhance accessibility through direct sales and pricing adjustments [6][25]. - In the autoimmune space, there is a growing concentration risk among major products from multinational corporations (MNCs), with new antibody platforms expected to yield significant data in 2026, potentially leading to new business development opportunities [7]. - The central nervous system (CNS) investment focus remains on advancing Aβ monoclonal antibody treatments, with key data expected to open up early intervention market opportunities [9]. Summary by Sections Oncology - The PD-1/VEGF dual antibody's clinical and industrial certainty is strengthening, with major companies conducting multiple global Phase III trials across high-value indications [17]. - The Pan-RAS precision therapy is entering a realization phase, with key Phase III data expected in 2026 for pancreatic cancer and NSCLC [22]. Metabolic - The cash-pay market for GLP-1 drugs is expanding due to limited insurance coverage, with companies like Eli Lilly and Novo Nordisk adopting different direct-to-consumer strategies to enhance accessibility [25][26]. - Small nucleic acid therapies are expected to upgrade treatment paradigms, showing competitive data in weight loss and safety profiles when combined with GLP-1 [30]. Autoimmune - MNCs are increasingly reliant on a few blockbuster products, with structural opportunities arising from new antibody platforms expected to report data in 2026 [7]. - The trend towards oral formulations in autoimmune diseases is gaining traction, offering advantages in adherence and competitive differentiation [7]. CNS - The focus in CNS remains on Aβ monoclonal antibody treatments, with advancements expected to shift treatment towards earlier intervention populations [9]. - New delivery methods, such as systemic administration of small nucleic acids, are being explored as complementary approaches [9].

格隆汇2月6日丨和黄医药(00013.HK)宣布，公司将于2026年3月5日(星期四)举行董事会会议，以(其中包 括)批准公司及其附属公司截至2025年12月31日止年度的年度业绩，并将其于同日下午7时正(香港时间) 发布。 ...

Core Viewpoint - HUTCHMED will announce its final results for the year ended December 31, 2025, on March 5, 2026, with subsequent webcasts for analysts and investors to discuss the results and conduct Q&A sessions [1][2]. Company Overview - HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on the discovery, global development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [4]. - The company has successfully marketed its first three medicines in China, with the first also receiving approval in the US, Europe, and Japan [4]. Event Details - The English webcast for discussing the final results will take place on March 5, 2026, at 8:00 am EST, followed by a Chinese (Putonghua) webcast on March 6, 2026, at 8:30 am HKT [2]. - Both webcasts will be available live on the company's website, with a replay accessible shortly after the events [3].

HUTCHMED (China) Limited 和黃醫藥（中國）有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對 因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：13） 董事會會議召開日期及 2025 年全年業績公告 和黃醫藥（中國）有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將於 2026 年 3 月 5 日（星期四） 舉行董事會會議，以（其中包括）批准本公司及其附屬公司截至 2025 年 12 月 31 日止年度之年度業績，並將其於同 日下午 7 時正（香港時間）發佈。 於業績獲批准及發佈後，本公司之管理層將於同日下午 9 時正（香港時間）舉行設有問答環節之英語網上直播簡報 會。本公司亦將於 2026 年 3 月 6 日（星期五）上午 8 時半（香港時間）舉行中文（普通話）網上直播。兩場實時網 上直播均可於本公司網站 www.hutch-med.com/event/ 收看。簡報文稿將於網上直播開始前上載至本公司網站以供 下載。 ...

Core Viewpoint - The Panamanian government has decided that future port concessions will not be granted to a single company, following a Supreme Court ruling that nullified CK Hutchison's contracts due to constitutional violations [1][2]. Group 1: Legal and Regulatory Developments - The Supreme Court of Panama nullified CK Hutchison's contract to operate two ports, citing exclusive privileges and tax exemptions as violations of the constitution [2]. - The Panamanian President stated that the court's decision is definitive and does not expect escalation of the situation [2]. - The enforcement timeline of the ruling remains unclear, but the Panama Ports Company will continue operations in the interim [3]. Group 2: Company Actions and Implications - CK Hutchison has initiated international arbitration proceedings against Panama, which could take years to resolve [3]. - The legal decision raises uncertainties regarding the future ownership of the two ports and impacts CK Hutchison's planned $23 billion sale of its port businesses [4]. Group 3: International Relations - China has warned Panama of "heavy prices" for the court ruling, labeling it as "absurd" and expressing intentions to defend the interests of Chinese companies [2].

I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00013 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,500,000,000 | USD | | 0.1 | USD | | 150,000,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | | | 本月底結存 | | | 1,500,000,000 | USD | | 0.1 | USD | | 150,000,000 | 本月底法定/註冊股本總額： USD 150,000,000 第 1 頁 共 10 頁 v 1.2.0 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交 ...

Core Viewpoint - The decision by Panama's top court to void CK Hutchison Holdings Ltd.'s contract to operate two ports has been criticized by a pro-Beijing newspaper, which claims the ruling is influenced by US pressure and urges Hong Kong businesses to reconsider investments in Panama [1][2][3]. Group 1: Judicial Independence and Economic Implications - The ruling reflects Panama's lack of judicial independence and its readiness to accommodate US demands, as stated in a commentary from Ta Kung Pao [2]. - The two ports are part of CK Hutchison's proposed sale of 43 global facilities to a consortium that includes China Cosco Shipping Corp., Terminal Investment Ltd., and BlackRock Inc. [2]. - The newspaper calls for Panama to correct the ruling and compensate affected companies, warning that failure to do so could harm economic ties with China and diminish confidence among Chinese enterprises [3]. Group 2: Geopolitical Context and Investment Risks - The article indicates rising tensions between the US and China over the strategic Panama Canal, complicating the ports sale by CK Hutchison, which could generate over $19 billion in cash if completed [4]. - CK Hutchison's decision to invite state-owned Cosco into the buying consortium was seen as a response to US pressure, with the US Secretary of State praising the ruling as a positive development [5][4]. - The commentary suggests that the ruling poses significant risks to global business operations and serves as a warning to investors [9]. Group 3: Strategic Moves and Future Considerations - To mitigate regulatory risks, the involved parties are considering splitting the assets into separate parcels with different ownership structures, allowing Cosco to take larger stakes in ports located in more China-friendly regions [6]. - The commentary criticizes Panama for its military cooperation with the US and for withdrawing from China's Belt and Road Initiative, indicating a shift in diplomatic relations [8]. - Prior to Cosco's involvement, China had threatened investigations into the deal and instructed state-owned enterprises to cease collaboration with the Li family, highlighting the political tensions affecting business operations [10].